CytRx
11
0
0
6
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 100/100
36.4%
4 terminated/withdrawn out of 11 trials
60.0%
-26.5% vs industry average
9%
1 trials in Phase 3/4
0%
0 of 6 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
Compassionate Use of Aldoxorubicin in Sarcoma Patients Chemotherapy
Role: lead
Tamibarotene and Arsenic Trioxide for Relapsed Acute Promyelocytic Leukemia
Role: collaborator
First Line Study of Tamibarotene in Combination for Advanced Non-Small Cell Lung Cancer
Role: lead
Study of Bafetinib as Treatment for Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL)
Role: lead
Safety, Efficacy, & Pharmacokinetic Study of Tamibarotene to Treat Patients With Relapsed or Refractory APL
Role: lead
Phase III Randomized Study of Poloxamer 188 for Vaso-Occlusive Crisis of Sickle Cell Disease
Role: collaborator
A Multicenter, Dose Ranging Safety and Pharmacokinetics Study of Arimoclomol in ALS
Role: lead
A Multicenter, Double-Blind Study to Investigate the Safety and Efficacy of Arimoclomol in Volunteers With ALS
Role: lead
INNO-206 in Patients With Small Cell Lung Cancer (SCLC)
Role: lead
Study of Bafetinib (INNO-406) as Treatment for Patients With Hormone-Refractory Prostate Cancer
Role: lead
Safety and Tolerability Study of INNO-406 to Treat Chronic Myeloid Leukemia or Acute Lymphocytic Leukemia
Role: lead
All 11 trials loaded